NovoCure (FRA:038) Cyclically Adjusted FCF per Share: €-0.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:038 NovoCure Ltd FRA:038
72 GF Score
Price €13.81
GF Value €16.21
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is NovoCure Cyclically Adjusted FCF per Share?

NovoCure FRA:038 +1.58% 72 Cyclically Adjusted FCF per Share is €-0.23 as of Mar. 2026. GuruFocus rates FRA:038 with a GF Score™ of 72/100 and a GF Value™ of €16.21 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

NovoCure's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.141. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.23 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-22), NovoCure's current stock price is €13.81. NovoCure's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.23. NovoCure's Cyclically Adjusted Price-to-FCF of today is .


NovoCure  (FRA:038) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


NovoCure Cyclically Adjusted FCF per Share Related Terms


NovoCure Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for NovoCure's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Cyclically Adjusted FCF per Share Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.41 -0.27

NovoCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.33 -0.28 -0.27 -0.23

FRA:038 vs ALMR, UFPT, NEOG: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted Price-to-FCF falls into.


FRA:038
72GF Score
NovoCure Ltd FRA:038
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NovoCure's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.141/330.2130*330.2130
=-0.141

Current CPI (Mar. 2026) = 330.2130.

NovoCure Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.376 241.018 -0.515
201609 -0.398 241.428 -0.544
201612 -0.187 241.432 -0.256
201703 -0.314 243.801 -0.425
201706 -0.072 244.955 -0.097
201709 0.007 246.819 0.009
201712 -0.046 246.524 -0.062
201803 -0.171 249.554 -0.226
201806 -0.084 251.989 -0.110
201809 0.040 252.439 0.052
201812 0.142 251.233 0.187
201903 -0.062 254.202 -0.081
201906 0.061 256.143 0.079
201909 0.103 256.759 0.132
201912 0.035 256.974 0.045
202003 -0.010 258.115 -0.013
202006 0.078 257.797 0.100
202009 0.220 260.280 0.279
202012 0.353 260.474 0.448
202103 0.113 264.877 0.141
202106 0.189 271.696 0.230
202109 0.173 274.310 0.208
202112 0.001 278.802 0.001
202203 -0.077 287.504 -0.088
202206 0.105 296.311 0.117
202209 0.161 296.808 0.179
202212 -0.091 296.797 -0.101
202303 -0.202 301.836 -0.221
202306 -0.258 305.109 -0.279
202309 -0.233 307.789 -0.250
202312 -0.183 306.746 -0.197
202403 -0.372 312.332 -0.393
202406 -0.114 314.175 -0.120
202409 -0.003 315.301 -0.003
202412 -0.109 315.605 -0.114
202503 -0.388 319.799 -0.401
202506 -0.166 322.561 -0.170
202509 0.114 324.800 0.116
202512 -0.174 324.054 -0.177
202603 -0.141 330.213 -0.141

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.23 mean?
NovoCure (FRA:038) has a Cyclically Adjusted FCF per Share of €-0.23 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on NovoCure and its competitors.
Is NovoCure's Cyclically Adjusted FCF per Share too high?
NovoCure's current Cyclically Adjusted FCF per Share is €-0.23. Overall, NovoCure has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Cyclically Adjusted FCF per Share compare to ALMR and UFPT?
NovoCure's Cyclically Adjusted FCF per Share of €-0.23 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on NovoCure and its competitors. NovoCure's current Cyclically Adjusted FCF per Share is €-0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (FRA:038) is currently considered Fairly Valued. The stock's GF Value™ is €16.21, compared to a current price of €13.81 — trading 14.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.23. NovoCure's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For NovoCure (FRA:038), the current Cyclically Adjusted FCF per Share is €-0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (FRA:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €13.81 is trading 14.8% below its estimated GF Value™ of €16.21. GuruFocus considers NovoCure to be Fairly Valued.

Key valuation signals for FRA:038:

  • Cyclically Adjusted FCF per Share: €-0.23
  • GF Value™: €16.21 vs. price of €13.81 (14.8% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the FRA:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
72GF Score

Get the complete analysis for FRA:038

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.81
Price
€16.21
GF Value